Galectin-3 in Papillary Thyroid Carcinoma

Sponsor

Sohag University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05699590

Collaborator

(none)

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Thyroid cancer is a common head and neck malignancy. It is the most common endocrine tumor in the body accounting for 1% of all cancers worldwide. The incidence of thyroid cancer varies worldwide. Most countries have reported an upward trend in its incidence.

Thyroid cancer encompass the most common well-differentiated papillary carcinoma (80% of all thyroid cancers) and follicular carcinoma (15%), as well as poorly differentiated carcinoma (< 1%) and anaplastic carcinoma (< 2%).

Papillary thyroid carcinomas (PTCs) are the most commonly encountered thyroid malignancies. The diagnosis of PTC is based on the special nuclear features such as overlapping of nuclei, intranuclear inclusions, optical clearing, anisonucleosis and nuclear grooves. However, it is often difficult to differentiate PTC from benign papillary thyroid hyperplasia . As differentiation between benign or malignant thyroid lesions has clinical, therapeutic, and prognostic significance, it is necessary to make accurate diagnosis by using biomarkers.

Recently, a large number of immunohistochemical (IHC) markers have been studied to assist in differentiating non-neoplastic lesions from malignant thyroid lesions. CK19, galectin-3, TG, Ki67, BRAF, calcitonin, HBME-1, TTF-1, and RET are some of the examples of these IHC markers.

Galectin-3 is a 31-kDa β-galactoside binding lectin. It has been shown to be expressed by several types of non-neoplastic and neoplastic cells, and it is involved in cell-cell adhesion and in cell-matrix interactions.

Condition or Disease	Intervention/Treatment	Phase
Galactin 3-thyroid Carcinoma

Study Design

Study Type:

Observational

Anticipated Enrollment :

60 participants

Observational Model:

Other

Time Perspective:

Retrospective

Official Title:

Galectin-3 Immunoreactivity in Papillary Thyroid Carcinoma

Anticipated Study Start Date :

Mar 1, 2023

Anticipated Primary Completion Date :

Mar 1, 2023

Anticipated Study Completion Date :

Jun 1, 2023

Outcome Measures

Primary Outcome Measures

Diagnosis and prognosis of papillary thyroid carcinoma both classic variant and follicular variant [Two or three days after staining tissue sections with Galactin 3 antibody]
evaluation of Galectin-3 Immunostaining in Papillary Thyroid Carcinoma

Eligibility Criteria

Criteria

Ages Eligible for Study:

20 Years to 90 Years

Sexes Eligible for Study:

All

Inclusion Criteria:

Thyroidectomy specimens both hemithyroidectomy and total thyroidectomy.
All the studied cases include sufficient materials for the immunohistochemical study.
Complete clinical data

Exclusion Criteria:

Patients with recurrence of the primary tumor.
Patients with a history of preoperative chemotherapy and/or radiotherapy.
Insufficient or tiny tissue biopsies

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Sohag University

Investigators

Principal Investigator: Amira Ahmed Abdelnaby, Lecturer, Pathology department, Faculty of medicine ,Sohag university

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Amira Ahmed Abdelnaby, Lecturer of pathology, Sohag University

ClinicalTrials.gov Identifier:

NCT05699590

Other Study ID Numbers:

Soh-Med-23-1-35

First Posted:

Jan 26, 2023

Last Update Posted:

Jan 27, 2023

Last Verified:

Jan 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Undecided

Plan to Share IPD:

Undecided

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Carcinoma

Thyroid Neoplasms

Thyroid Cancer, Papillary

Thyroid Diseases

Study Results

No Results Posted as of Jan 27, 2023